Sight Sciences, Inc. (SGHT)
NASDAQ (NGS) NASDAQ (NGS) Primary Summary
Sight Sciences: Signs Of Progress, But Plenty Of Work Remains
Sight Sciences is a cautious 'buy,' as recent reimbursement wins and product momentum support a positive outlook, offset by liquidity pressures and ongoing reimbursement and utilization challenges. SGHT's OMNI Ultra Surgical System launch and updated TearCare label provide incremental adoption tailwinds, but procedure costs/reimbursement and surgeon preference remain key hurdles. Q2 revenue grew 20% with strong dry eye business acceleration, improved gross margins, and reduced cash burn; Aetna coverage adds 25 million insured lives to the glaucoma business.
Sight Sciences, Inc. (SGHT) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Sight Sciences, Inc. (SGHT) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Sight Sciences Q2 Earnings Call Highlights
Sight Sciences NASDAQ: SGHT reported second-quarter revenue growth of 20% year over year, supported by gains in its interventional glaucoma and interventional dry eye businesses, while reducing operating expenses and cash usage. The company raised its full-year revenue outlook and lowered its adjusted operating expense guidance.
Sight Sciences, Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 Curtis Ellergodt Rothschild Investment LLC | 43 | $232.08 | $354.75 | $122.67 | 52.86% |
| KJD Kathryn J. Daniels Canada Pension Plan Investment Board | 55,100 | $273,455 | $456,228 | $182,773 | 66.84% |
| CD Charlie Durham Sterling Capital Management LLC | 129 | $1,022.89 | $1,064.25 | $41.36 | 4.04% |
 Point72 Asset Management LP Point72 Asset Management LP | 16,125 | $60,791.21 | $141,900 | $81,108.79 | 133.42% |
 Shawn M. McHugh WealthTrust Asset Management LLC | 20,956 | $73,913.21 | $183,993.68 | $110,080.47 | 148.93% |
Sight Sciences, Inc. (SGHT) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Sight Sciences, Inc. ever had a stock split?
Sight Sciences, Inc. Profile
| Health Care Equipment & Supplies Industry | Healthcare Sector | Paul Badawi CEO | NASDAQ (NGS) Exchange | 82657M105 CUSIP |
| US Country | 186 Employees | - Last Dividend | - Last Split | 15 Jul 2021 IPO Date |
Overview
Sight Sciences, Inc. is an esteemed entity in the realm of ophthalmic medical devices, primarily engaged in innovating both surgical and non-surgical solutions aimed at the treatment of various eye conditions. With a keen focus on addressing eye diseases such as glaucoma and dry eye disease, the company channels its efforts through two main operational segments: Surgical Glaucoma and Dry Eye. Founded in 2010, Sight Sciences has positioned its headquarters in Menlo Park, California, showcasing a commitment towards advancing ophthalmic care. The company's operational strategy encompasses the provision of its cutting-edge products to healthcare facilities, hospitals, and eye care professionals across the United States, facilitated through a network of dedicated sales representatives and distributors. This strategic approach underscores its mission to enhance the standard of eye care with innovative solutions accessible to a broad patient demographic.
Products and Services
- OMNI Surgical System
- SION Surgical Instrument
- TearCare System
A pioneering technology in the field of glaucoma surgery, the OMNI Surgical System stands out as an implant-free solution designed to mitigate intraocular pressure among adults diagnosed with primary open-angle glaucoma. This breakthrough device epitomizes the company's commitment to advancing surgical interventions that offer hope and improved quality of life for glaucoma patients.
The SION Surgical Instrument represents an innovative manually operated tool integral for ophthalmic surgical procedures, primarily focusing on the excision of trabecular meshwork. This instrument underscores Sight Sciences' dedication to refining surgical tools that enhance the precision and outcomes of eye surgeries.
Addressing the prevalent issue of evaporative dry eye disease resultant from meibomian gland dysfunction, the TearCare System emerges as a wearable eyelid technology designed for adult patients. This solution emphasizes the company's focus on non-surgical treatment options, providing a patient-friendly approach to managing dry eye conditions effectively.
Contact Information
